Ocugen Q1 net loss $0.05/share, cash $26.4M; OCU400 Phase 3 underway

Ocugen, Inc.

2024-Q1 EPS reported -$0.05 revenue$1,014,000

Net loss $0.05/share for Q1 2024 vs $0.08 loss in Q1 2023; total operating expenses $13.2M, down 29% YoY.
Cash and cash equivalents $26.4M at March 31, 2024, versus $39.5M at December 31, 2023.
OCU400 Phase 3 liMeliGhT trial cleared by FDA; dosing begins Q2 2024; EMA supports MAA submission.
OCU410 (dAMD) cohort 2 dosing complete; Phase 2 expansion expected Q3 2024. OCU410ST cohort 2 enrollment initiated.
NeoCart GMP facility renovated; Phase 3 contingent on funding. OCU500 IND planned mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ocugen, Inc. reported first quarter 2024 results: net income a $0.05 net loss per common share, EPS a $0.05 net loss per common share.

Period: first quarter 2024
Net income: a $0.05 net loss per common share
EPS: a $0.05 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ocugen, Inc. reported three months ended March 31, 2024 results: net income Total operating expenses for the three months ended March 31, 2024 were $13.2 million, EPS a $0.05 net loss per common share.

Period: three months ended March 31, 2024
Net income: Total operating expenses for the three months ended March 31, 2024 were $13.2 million
EPS: a $0.05 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-023179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.